Metagenomi, Inc. (MGX)
NASDAQ:MGX
Want to see MGX full AI Analyst Report?
Top Page
Metagenomi, Inc.
(NASDAQ:MGX)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.50
▲(1.35% Upside)
Action:Reiterated
Date:05/14/26
The score is held down primarily by very weak financial performance (large, persistent losses and heavy negative free cash flow) and bearish technicals (price below key moving averages with negative MACD). Offsetting this partially are positive corporate updates, including stated cash runway through Q4 2027 and progress toward upcoming regulatory milestones, but valuation remains unattractive in traditional terms due to ongoing unprofitability.
Positive Factors
Cash runway through Q4 2027
A reported $140.2M cash position providing runway into Q4 2027 gives multi-year funding to advance regulatory submission and a 2027 trial start. This durable runway reduces immediate financing pressure and supports multi-stage program execution, assuming planned milestones are met.
Negative Factors
High cash burn and negative free cash flow
TTM operating and free cash flow near -$87M indicate persistent heavy cash burn that will erode runway if timelines slip or spending resumes. Ongoing negative FCF forces reliance on external financing, which can dilute shareholders and constrain long-term strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash runway through Q4 2027
A reported $140.2M cash position providing runway into Q4 2027 gives multi-year funding to advance regulatory submission and a 2027 trial start. This durable runway reduces immediate financing pressure and supports multi-stage program execution, assuming planned milestones are met.
Read all positive factors
Metagenomi, Inc. (MGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$51.20M
Dividend YieldN/A
Average Volume (3M)883.52K
Price to Earnings (P/E)―
Beta (1Y)1.00
Revenue Growth-50.66%
EPS Growth-9.30%
CountryUS
Employees202
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.30
Shares Outstanding37,646,860
10 Day Avg. Volume1,405,864
30 Day Avg. Volume883,524
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.38
Price to Sales (P/S)2.39
P/FCF Ratio-0.67
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue2.91
Enterprise Value/Gross Profit-23.24
Enterprise Value/Ebitda-0.77
Forecast
1Y Price Target
$8.00Price Target Upside440.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.12
Revenue Forecast (FY)$12.15M
Metagenomi, Inc. Business Overview & Revenue Model
Company Description
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, ...
How the Company Makes Money
Metagenomi’s revenue model is primarily based on partnering and licensing its gene-editing platform and related intellectual property to other life-science companies. Key revenue streams typically include (1) upfront payments received when enterin...
Metagenomi, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.33M | 25.21M | 52.30M | 44.76M | 17.20M | 243.00K |
| Gross Profit | -2.80M | 19.89M | 52.30M | -49.65M | 15.47M | -144.00K |
| EBITDA | -85.07M | -90.70M | -83.49M | -74.28M | -39.19M | -20.75M |
| Net Income | -85.89M | -87.87M | -78.06M | -68.25M | -43.59M | -21.44M |
Balance Sheet | ||||||
| Total Assets | 196.95M | 221.10M | 324.60M | 364.84M | 414.49M | 141.99M |
| Cash, Cash Equivalents and Short-Term Investments | 140.16M | 160.80M | 248.31M | 271.18M | 362.13M | 108.15M |
| Total Debt | 39.19M | 40.66M | 45.78M | 48.23M | 18.57M | 48.93M |
| Total Liabilities | 59.17M | 62.51M | 89.74M | 149.67M | 488.91M | 174.54M |
| Stockholders Equity | 137.78M | 158.60M | 234.86M | 215.17M | -74.43M | -32.54M |
Cash Flow | ||||||
| Free Cash Flow | -87.54M | -89.47M | -112.19M | -101.22M | 15.75M | 21.35M |
| Operating Cash Flow | -87.22M | -88.89M | -109.07M | -91.41M | 29.72M | 24.26M |
| Investing Cash Flow | 82.79M | 103.53M | -88.16M | 45.73M | -122.20M | -74.32M |
| Financing Cash Flow | -306.00K | -356.00K | 84.01M | 1.01M | 239.59M | 39.92M |
Metagenomi, Inc. Technical Analysis
Neutral
1.48
Price Trends
1.39
Negative
1.48
Negative
1.78
Negative
Market Momentum
-0.02
Negative
48.78
Neutral
72.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGX, the sentiment is Neutral. The current price of 1.48 is above the 20-day moving average (MA) of 1.36, above the 50-day MA of 1.39, and below the 200-day MA of 1.78, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 48.78 is Neutral, neither overbought nor oversold. The STOCH value of 72.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MGX.
Metagenomi, Inc. Risk Analysis
Metagenomi, Inc. disclosed 77 risk factors in its most recent earnings report. Metagenomi, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Metagenomi, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $162.48M | 1.47 | 60.96% | ― | -100.00% | ― | |
59 Neutral | $203.78M | -4.32 | -220.75% | ― | ― | 38.59% | |
55 Neutral | $261.86M | ― | -59.95% | ― | ― | -24.56% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $94.70M | ― | 25.68% | ― | -88.41% | 76.14% | |
46 Neutral | $51.20M | -0.60 | -51.23% | ― | -50.66% | -9.30% | |
40 Underperform | $21.87M | -0.39 | -208.23% | ― | -100.00% | 26.30% |
* Healthcare Sector Average
MGX
Metagenomi, Inc.
1.36
-0.40
-22.73%
ORMP
Oramed Pharm
3.97
1.75
78.99%
IMUX
Immunic
14.96
7.96
113.71%
ATRA
Atara Biotherapeutics
10.51
2.51
31.37%
HOWL
Werewolf Therapeutics
0.45
-0.75
-62.50%
CNTX
Context Therapeutics
2.85
2.26
384.69%
Metagenomi, Inc. Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Metagenomi Highlights Q1 Progress on MGX-001 Gene Therapy
Positive
May 11, 2026
Metagenomi Therapeutics reported first quarter 2026 results on May 11, 2026, highlighting progress on its MGX-001 hemophilia A program and platform technologies while maintaining a cash position of $140.2 million, which it expects will fund operat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.